Excalibur Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.99M | Sell |
21,447
-125
| -0.6% | -$17.5K | 1.07% | 24 |
|
|
2025
Q4 | $2.65M | Sell |
21,572
-413
| -2% | -$50.2K | 0.95% | 28 |
|
|
2025
Q3 | $2.44M | Sell |
21,985
-134
| -0.6% | -$15.2K | 0.89% | 28 |
|
|
2025
Q2 | $2.45M | Sell |
22,119
-782
| -3% | -$83.2K | 0.92% | 26 |
|
|
2025
Q1 | $2.57M | Sell |
22,901
-341
| -1% | -$35.2K | 1.01% | 24 |
|
|
2024
Q4 | $2.15M | Sell |
23,242
-152
| -0.6% | -$13.7K | 0.85% | 28 |
|
|
2024
Q3 | $1.96M | Sell |
23,394
-549
| -2% | -$41.9K | 0.75% | 34 |
|
|
2024
Q2 | $1.64M | Buy |
23,943
+1,081
| +5% | +$72.1K | 0.67% | 37 |
|
|
2024
Q1 | $1.67M | Buy |
22,862
+1,010
| +5% | +$77.7K | 0.71% | 35 |
|
|
2023
Q4 | $1.77M | Sell |
21,852
-284
| -1% | -$22.1K | 0.83% | 31 |
|
|
2023
Q3 | $1.66M | Buy |
22,136
+171
| +0.8% | +$13.2K | 0.86% | 27 |
|
|
2023
Q2 | $1.69M | Sell |
21,965
-780
| -3% | -$62.2K | 0.86% | 27 |
|
|
2023
Q1 | $1.89M | Sell |
22,745
-135
| -0.6% | -$11.2K | 0.98% | 25 |
|
|
2022
Q4 | $1.96M | Sell |
22,880
-920
| -4% | -$72.9K | 1.03% | 23 |
|
|
2022
Q3 | $1.47M | Buy |
23,800
+55
| +0.2% | +$3.47K | 0.82% | 29 |
|
|
2022
Q2 | $1.47M | Buy |
23,745
+15
| +0.1% | +$929 | 0.76% | 35 |
|
|
2022
Q1 | $1.41M | Buy |
23,730
+3,917
| +20% | +$250K | 0.61% | 46 |
|
|
2021
Q4 | $1.44M | Buy |
19,813
+66
| +0.3% | +$4.55K | 0.58% | 44 |
|
|
2021
Q3 | $1.38M | Buy |
19,747
+354
| +2% | +$24.9K | 0.6% | 42 |
|
|
2021
Q2 | $1.33M | Buy |
19,393
+1,885
| +11% | +$126K | 0.6% | 42 |
|
|
2021
Q1 | $1.13M | Sell |
17,508
-267
| -2% | -$17.2K | 0.56% | 47 |
|
|
2020
Q4 | $1.04M | Sell |
17,775
-149
| -0.8% | -$8.99K | 0.56% | 45 |
|
|
2020
Q3 | $1.13M | Buy |
17,924
+3,262
| +22% | +$226K | 0.69% | 36 |
|
|
2020
Q2 | $1.13M | Buy |
14,662
+3,059
| +26% | +$234K | 0.75% | 36 |
|
|
2020
Q1 | $867K | Buy |
11,603
+1,864
| +19% | +$129K | 0.67% | 39 |
|
|
2019
Q4 | $633K | Sell |
9,739
-3,315
| -25% | -$216K | 0.41% | 53 |
|
|
2019
Q3 | $827K | Buy |
13,054
+243
| +2% | +$15.9K | 0.74% | 38 |
|
|
2019
Q2 | $866K | Buy |
12,811
+280
| +2% | +$18.4K | 0.8% | 37 |
|
|
2019
Q1 | $815K | Sell |
12,531
-25
| -0.2% | -$1.66K | 0.77% | 38 |
|
|
2018
Q4 | $785K | Sell |
12,556
-800
| -6% | -$55.9K | 0.79% | 34 |
|
|
2018
Q3 | $1.03M | Sell |
13,356
-265
| -2% | -$20K | 0.88% | 30 |
|
|
2018
Q2 | $965K | Buy |
13,621
+85
| +0.6% | +$6K | 0.77% | 37 |
|
|
2018
Q1 | $1.02M | Sell |
13,536
-2,888
| -18% | -$230K | 0.83% | 36 |
|
|
2017
Q4 | $1.18M | Sell |
16,424
-6,703
| -29% | -$509K | 0.99% | 28 |
|
|
2017
Q3 | $1.87M | Buy |
23,127
+240
| +1% | +$18.4K | 1.59% | 17 |
|
|
2017
Q2 | $1.62M | Sell |
22,887
-341
| -1% | -$22.7K | 1.45% | 18 |
|
|
2017
Q1 | $1.58M | Sell |
23,228
-50
| -0.2% | -$3.52K | 1.4% | 19 |
|
|
2016
Q4 | $1.67M | Sell |
23,278
-11,467
| -33% | -$852K | 1.52% | 19 |
|
|
2016
Q3 | $2.75M | Buy |
34,745
+700
| +2% | +$56.9K | 2.61% | 15 |
|
|
2016
Q2 | $2.84M | Buy |
34,045
+145
| +0.4% | +$12.9K | 2.44% | 17 |
|
|
2016
Q1 | $3.11M | Buy |
33,900
+4,535
| +15% | +$409K | 2.79% | 11 |
|
|
2015
Q4 | $2.97M | Buy |
29,365
+365
| +1% | +$38K | 2.76% | 12 |
|
|
2015
Q3 | $2.85M | Buy |
29,000
+7,777
| +37% | +$864K | 2.85% | 14 |
|
|
2015
Q2 | $2.48M | Buy |
21,223
+840
| +4% | +$91.8K | 2.33% | 17 |
|
|
2015
Q1 | $2M | Buy |
20,383
+17,508
| +609% | +$1.78M | 1.93% | 20 |
|
|
2014
Q4 | $271K | Buy |
+2,875
| New | +$297K | 0.27% | 48 |
|
Other funds holding GILD
VCM
VPM
Excalibur Management's GILD Position: Q1 2026 in Review
Excalibur Management reduced its Gilead Sciences (GILD) stake by 0.58% in Q1 2026, selling an estimated $17.5K and leaving 21,447 shares worth $2.99M. The position accounts for 1.07% of the portfolio, ranked #24.
Excalibur Management first reported a position in GILD in Q4 2014 and has held it in 46 quarters since. The position peaked at $3.11M in Q1 2016. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Excalibur Management held 21,447 shares of Gilead Sciences worth $2.99M as of Q1 2026.
- Excalibur Management sold 125 Gilead Sciences shares in Q1 2026, an estimated $17.5K.
- Gilead Sciences made up 1.07% of Excalibur Management's portfolio in Q1 2026, its #24 holding.
- Excalibur Management first reported a position in Gilead Sciences in Q4 2014 and has held it in 46 quarters since.
- Excalibur Management's Gilead Sciences position peaked at $3.11M in Q1 2016.
- 2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Excalibur Management's 13F filing for Q1 2026, filed 5 May 2026.